BOS-356 / GSK, Boston Pharma - LARVOL DELTA

Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of Repeat Topical Application of BOS-356 in Subjects With Moderate to Severe Acne Vulgaris (clinicaltrials.gov) - P1; N=66; Completed; Sponsor: Boston Pharmaceuticals; Recruiting ➔ Completed; Trial completion date: May 2021 ➔ Nov 2020; Trial primary completion date: May 2021 ➔ Nov 2020

Clinical • Trial completion • Trial completion date • Trial primary completion date • Acne Vulgaris • Dermatology

Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of Repeat Topical Application of BOS-356 in Subjects With Moderate to Severe Acne Vulgaris (clinicaltrials.gov) - P1; N=66; Recruiting; Sponsor: Boston Pharmaceuticals; Trial completion date: Aug 2020 ➔ May 2021; Trial primary completion date: Aug 2020 ➔ May 2021

Clinical • Trial completion date • Trial primary completion date • Acne Vulgaris • Dermatology

A Population Analysis of the DGAT1 Inhibitor GSK3008356 and its Effect on Endogenous and Meal-Induced Triglyceride Turnover in Healthy Subjects. (PubMed, Fundam Clin Pharmacol) - "The current analysis presents a PKPD modeling strategy of time-varying TG data coming from both endogenous and exogenous sources. In general, the presented model could be utilized in the model-based drug development of drugs that influence TG levels in blood."

Clinical • Journal

Newly added product (clinicaltrials.gov) - P1, Dermatology

Pipeline update